title: [Clinical obervation of Jiedu Tongluo Lishi decoction on treating reactive rheumatoid arthritis].
abstract: OBJECTIVE
  To explore the clinical curative effect and safety of Jiedu Tongluo Lishi decoction on treating active rheumatoid arthritis (RA).
  
  
  METHODS
  106 cases of RA in active period were randomly divided into the integrated Chinese and western medicine group (n=54) and western medicine contrast group (n=52). The former group were treated by Jiedu Tongluo Lishi decoction combined with SASP, the latter by MTX combined with SASP. The arthritis morning stiffness time, ache indexes, tumidness indexes, function indexes, hands grip, 20-m walking time and experimental indexes including ESR, RF, CRP, C3, immune globin of both groups were observed and compared.
  
  
  RESULTS
  The obviously clinical effective ratio and the total clinical effective ratio in the former group were 77.78% and 90.74% respectively, which are better than those in the latter group (59.62% and 71.15% respectively) (P < 0.01). The arthritis morning stiffness time, ache indexes, tumidness indexes, function indexes, hands grip and 20-m walking time in both groups were obviously released after treatment (P < 0.01). The clinical release in the former group was better than that in the latter group (P < 0.05). ESR, RF and CRP in both groups were markedly improved (P < 0.05). The improvement of ESR, RF, CRP, C3 and IgA in the former group were better than those in the latter group (P < 0.05). The side effect includes gastroenteric tract reaction, decrease of leucocyte, abnormity of liver function, tetter and catamenia maladjustment. The occurent ratio in the former group was 7.41%, which was obviously lower than that in the latter group (15.38%) (P < 0.01).
  
  
  CONCLUSIONS
  The compositively clinical curative effect of Jiedu Tongluo Lishi decoction combined with MTX on treating RA is obviously better than that of western medicine only such as MTX and SASP, with less side effect and higher safety, which is worth applying in clinics extensively.
authors: Zhejiang Traditional Chinese Medical and Medicine University, Hangzhou 310006, China.
authors: Cheng-pin
authors: CP
authors: Wen
authors: Chen-yu
authors: CY
authors: Jin
authors: Zhi-liang
authors: ZL
authors: Xu
authors: Lin-yong
authors: LY
authors: Cao
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000302:isolation & purification / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D015232:Dinoprostone / Q000097:blood; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000627:therapeutic use*; D005260:Female; D005620:Freund's Adjuvant; D053583:Interleukin-1beta / Q000097:blood; D008297:Male; D008419:Materia Medica / Q000302:isolation & purification / Q000627:therapeutic use; D008516:Medicine, Chinese Traditional; D051379:Mice; D017288:Pain Threshold / Q000187:drug effects; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012605:Scorpions / Q000737:chemistry; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D018501:Antirheumatic Agents; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D053583:Interleukin-1beta; D008419:Materia Medica; D014409:Tumor Necrosis Factor-alpha; C534053:jiedu tongluo lishi; D005620:Freund's Adjuvant; D015232:Dinoprostone